Incyte bags Pemazyre FDA approval for cholangiocarcinoma treatment
Pemazyre FDA approval : US biopharma company Incyte has bagged accelerated approval from the US Food and Drug Administration (FDA) for Pemazyre (pemigatinib) for the ... Read More
Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma
Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or ... Read More
Innovent Biologics and Incyte announce $391.5m partnership for cancer drugs in China
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational ... Read More